A population-based study of dosing and persistence with anti-dementia medications

Brewer et al. (2013) assessed the adequacy of dosing and persistence with AD medications (anti-cholinesterase inhibitors and Memantine) and predictors (age, gender and drug sub-type) of these variables in the ‘real world’, i.e. outside the clinical trial setting.  Using prescription refill information from the HSE Primary Care Reimbursement Services pharmacy claims database in ROI, the study found a substantial increase in the rate of prescribing of AD drugs between 2007 and 2010. Donepezil and Memantine were the most frequently prescribed AD drugs with a significant proportion of patients initiated on these drugs prescribed the maximum dose. However, only two-thirds of patients maintained this dose for at least two consecutive months, suggesting that there may be room for improvement in optimising the prescribing of AD medications, and a need to investigate the reasons why these medications are stopped. 

Title: 
A population-based study of dosing and persistence with anti-dementia medications
Date: 
2013
References: 

BREWER. L., BENNETT, K., MCGREEVY, C. and WILLIAMS, D. 2013. A population-based study of dosing and persistence with anti-dementia medications. European Journal of Clinical Pharmacology. 69, pp. 1467–1475.